Visit COVID-19 resources

[Skip to Content]

Protecting retinal ganglion cells – (Eye 31, 218 (February 2017))

Feb 09
2017

Protecting retinal ganglion cells Eye 31, 218 (February 2017). doi:10.1038/eye.2016.299 Authors: T Z Khatib & K R Martin

  • 9 February 2017

Biomarkers for glaucoma: from the lab to the clinic – (Eye 31, 225 (February 2017))

Feb 09
2017

Biomarkers for glaucoma: from the lab to the clinic Eye 31, 225 (February 2017). doi:10.1038/eye.2016.300 Authors: N Von Thun Und Hohenstein-Blaul, S Kunst, N Pfeiffer & F H Grus

  • 9 February 2017

Fingolimod: therapeutic mechanisms and ocular adverse effects – (Eye 31, 232 (February 2017))

Feb 09
2017

Fingolimod: therapeutic mechanisms and ocular adverse effects Eye 31, 232 (February 2017). doi:10.1038/eye.2016.258 Authors: P Mandal, A Gupta, W Fusi-Rubiano, P A Keane & Y Yang

  • 9 February 2017

Uveal melanoma: relatively rare but deadly cancer – (Eye 31, 241 (February 2017))

Feb 09
2017

Uveal melanoma: relatively rare but deadly cancer Eye 31, 241 (February 2017). doi:10.1038/eye.2016.275 Authors: S Kaliki & C L Shields

  • 9 February 2017

The evidence informing the surgeon’s selection of intraocular lens on the basis of light transmittance properties – (Eye 31, 258 (February 2017))

Feb 09
2017

The evidence informing the surgeon’s selection of intraocular lens on the basis of light transmittance properties Eye 31, 258 (February 2017). doi:10.1038/eye.2016.266 Authors: X Li, D Kelly, J M Nolan, J L Dennison & S Beatty

  • 9 February 2017